Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced CancersRamesh K. Ramanathan, Chandra P. Belani(Penn State Milton S. Hershey Medical Center)Clinical Cancer ResearchMarch 15, 200710.1158/1078-0432.ccr-06-2233Cited by 87SaveCiteExport RISWatch citationsRelated PapersTrametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer|PLoS ONE|2015|61EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer|PLoS ONE|2019|12